Inactive Instrument

Highlights Genmab Nasdaq Copenhagen

Equities

DK0010272202

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Genmab A/S Reaffirms Financial Guidance for 2024	May. 21	CI
Genmab A/S completed the acquisition of ProfoundBio, Inc.	May. 20	CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	May. 15	MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress	May. 14	CI
GENMAB : A good start to 2024; guidance unchanged	May. 03
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	May. 02	MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	May. 02	MT
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	Apr. 30	MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	Apr. 29	CI
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	Apr. 16	MT
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Health Care Flat on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	Apr. 03	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	Apr. 03	DJ
Global markets live: Swiss Re, Intel, Walt Disney, Paramount, Microsoft...	Apr. 03
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	Apr. 03	DJ
Correction to Genmab Article	Apr. 03	DJ
Genmab: acquisition of ProfoundBio greeted without emotion	Apr. 03	CF
News Highlights : Top Company News of the Day - Wednesday at 7 AM ET	Apr. 03	DJ
Genmab A/S Re-Affirms Revenue Guidance for the Year 2024	Apr. 03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT